BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case

M. M. Davydov; Давыдов М. М.; P. A. Zeynalova; Зейналова П. А.; A. A. Fedenko; Феденко А. А.; D. A. Chekiny; Чекини Д. А.; E. K. Ibragimov; Ибрагимов Э. К.; A. A. Filimonov; Филимонов А. А.; O. V. Sinitsyna; Синицына О. В.; E. A. Bogush; Богуш Е. А.; M. A. Chekalova; Чекалова М. А.; G. F. Allakhverdieva; Аллахвердиева Г. Ф.; M. V. Shamanova; Шаманова М. Б.; I. V. Zhguleva; Жгулева И. В.; V. Yu. Kirsanov; Кирсанов В. Ю.; V. E. Ponomarev; Пономарeв В. Е.; S. B. Polikarpova; Поликарпова С. Б.; T. T. Valiev; Валиев Т. Т.; M. A. Kurtser; Курцер М. А.

doi:10.17650/2782-3202-2021-1-1-38-42

BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case

Authors: Davydov M.M.¹^,2, Zeynalova P.A.¹^,2, Fedenko A.A.¹, Chekiny D.A.¹, Ibragimov E.K.¹, Filimonov A.A.¹, Sinitsyna O.V.¹, Bogush E.A.¹^,2, Chekalova M.A.¹, Allakhverdieva G.F.¹, Shamanova M.V.³, Zhguleva I.V.³, Kirsanov V.Y.², Ponomarev V.E.², Polikarpova S.B.², Valiev T.T.², Kurtser M.A.¹^,4
Affiliations:
1. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
2. I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
3. Clinical Hospital MD GROUP
4. N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Issue: Vol 1, No 1 (2021)
Pages: 38-42
Section: RARE NEOPLASMS AND COMPLEX CLINICAL SITUATIONS: DIFFICULTIES IN DIAGNOSIS AND SELECTION OF TREATMENT TACTICS
Published: 05.12.2021
URL: https://mdonco.abvpress.ru/jour/article/view/6
DOI: https://doi.org/10.17650/2782-3202-2021-1-1-38-42
ID: 6

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Per the majority of authors, melanoma is the most common tumor diagnosed during pregnancy (31 % of all malignant neoplasms). In approximately 1/3 of women melanoma developed in child-bearing age is diagnosed during pregnancy or in the postpartum period. However, only some retrospective studies analyzed the effect of pregnancy on melanoma development, and conclusive data on development, progression and treatment of BRAF-mutant melanoma is lacking. In this subpopulation of patients, BRAF status supposedly can negatively affect disease outcome irrespective of treatment methods.
The article presents a clinical case of recurrence of melanoma with the BRAF V600E mutation during pregnancy. The patient underwent lymph node dissection during pregnancy prolongation, after labor she received antitumor drug therapy with МЕК and ВRAF inhibitors. Melanoma recurrence during pregnancy did not worsen treatment outcomes for the mother and embryo.

Keywords

melanoma, BRAF mutation, pregnancy, BRAF/MEK inhibitors

About the authors

M. M. Davydov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0001-5038-9307

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia

Russian Federation

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0003-1564-424X

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia

Russian Federation

A. A. Fedenko

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0003-4927-5585

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Russian Federation

D. A. Chekiny

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Russian Federation

E. K. Ibragimov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Russian Federation

A. A. Filimonov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Russian Federation

O. V. Sinitsyna

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Russian Federation

E. A. Bogush

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Author for correspondence.
Email: elena_bogush@yahoo.com
ORCID iD: 0000-0001-5601-3669

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia

Russian Federation

M. A. Chekalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Russian Federation

G. F. Allakhverdieva

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0001-5910-5892

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Russian Federation

M. V. Shamanova

Clinical Hospital MD GROUP

Bld. 1, 24 Sevastopolsky Ave, Moscow 117209, Russia

Russian Federation

I. V. Zhguleva

Clinical Hospital MD GROUP

Bld. 1, 24 Sevastopolsky Ave, Moscow 117209, Russia

Russian Federation

V. Yu. Kirsanov

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0003-0040-3136

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia

Russian Federation

V. E. Ponomarev

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0003-0153-3311

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia

Russian Federation

S. B. Polikarpova

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0003-3621-7394

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia

Russian Federation

T. T. Valiev

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0002-1469-2365

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia

Russian Federation

M. A. Kurtser

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-0175-1968

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

1 Ostrovityanova St., Moscow 117997, Russia

Russian Federation

References

De Haan J., van Thienen J.V., Casaer M. et al. Severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma. Case Rep Oncol 2018;11(1):119–24. doi: 10.1159/000487128.
Bucheit A.D., Hardy J.T., Szender J.B. et al. Conception and viable twin pregnancy in a patient with metastatic melanoma treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res 2020;30(4):423–5. doi: 10.1097/CMR.0000000000000657.
Ziogas D.C., Diamantopoulos P., Benopoulou O. et al. Prognosis and management of BRAF V600E-mutated pregnancy-associated melanoma. Oncol 2020;25(8):1209–20. doi: 10.1634/theoncologist.2019-0747.
Jones M.S., Lee J., Stern S.L. et al. Is pregnancy-associated melanoma associated with adverse outcomes? J Am Coll Surg 2017;225(1):149–58. doi: 10.1016/j.jamcollsurg.2017.02.011.
Todd S.P., Driscoll M.S. Prognosis for women diagnosed with melanoma during, before, or after pregnancy: weighing the evidence. Int J Womens Dermatol 2017;3(1):26–9. doi: 10.1016/j.ijwd.2016.12.004.
Zelin E., Conforti C., Giuffrida R. et al. Melanoma in pregnancy: certainties unborn. Melanoma Manag 2020;7(3):MMT48. doi: 10.2217/mmt-2020-0007.
Kyrgidis A., Lallas A., Moscarella E. Does pregnancy influence melanoma prognosis? A meta-analysis. Melanoma Res 2017;27(4):289–99. doi: 10.1097/CMR.0000000000000334.
Walker J.L., Wang A.R., Kroumpouzos G., Weinstok M.A. Melanoma in pregnancy. In: Melanoma: a modern multidisciplinary approach. Ed by A.I. Riker. Springer, Cham, 2018. Pp. 239–252.
Still R., Brennecke S. Melanoma in pregnancy. Obstet Med 2017;10(3):107–12. doi: 10.1177/1753495X17695001.
Garbe C., Amaral T., Peris K. et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. Eur J Cancer 2020;126:141–58. doi: 10.1016/j.ejca.2019.11.014.
Ribero S., Longo C., Dika Е. et al. Pregnancy and melanoma: a European-wide survey to assess current management and critical literature overview. J Eur Acad Dermatol Venereol 2017;31(1):65–9. doi: 10.1111/jdv.13722.
Menzer C., Beedgen B., Rom J. et al. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. Eur J Cancer 2018;104:239–42. doi: 10.1016/j.ejca.2018.09.008.
Xu W., Moor R.J., Walpole E.T. et al. Pregnancy with successful fetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: Case report and review of the literature. Melanoma Res 2019;29(3):333–7. doi: 10.1097/CMR.0000000000000586.
Mehta A., Kim K.B., Minor D.R. Case report of a pregnancy during ipilimumab therapy. J Glob Oncol 2018;4:1–3. doi: 10.1200/JGO.17.00019.
Burotto M., Gormas J.G., Samtani S. et al. Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Semin Oncol 2018;45(3):164–9. doi: 10.1053/j.seminoncol.2018.03.003.
Sacchetto L., Zanetti R., Comber H. et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018;92:108–18. doi: 10.1016/j.ejca.2017.12.024

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register